Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05201469 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

VIBRANT: VIB4920 for Active Lupus Nephritis

Study acronym: VIBRANT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 9 months later Aug 2026 → Jun 2028
See other at-risk trials from National Institute of Allergy and Infectious Diseases (NIAID)

Record History

  1. Primary completion pushed from Aug 2026 to Jun 2028 Start date: May 16, 2022 to Dec 15, 2022 · Completion pushed from Mar 2027 to Dec 2028 · Eligibility criteria expanded, about 44 words · 3 more Show 6 more changesShow less
    • Start date: May 16, 2022 to Dec 15, 2022
    • Completion pushed from Mar 2027 to Dec 2028
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 7 of 14 entries
    • Site details revised at 5 of 17 sites
    • Study description expanded, about 2 words
  2. Study sites: 18 to 17v20
  3. Study sites: 17 to 18v19
  4. Eligibility criteria shortened, about 14 words Secondary endpoints revised (14) · Study description expanded, about 105 words · Site contacts updated at 5 of 17 sitesv18 Show 3 more changesShow less
    • Secondary endpoints revised (14)
    • Study description expanded, about 105 words
    • Site contacts updated at 5 of 17 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Site contacts updated at 1 of 17 sitesv17
Show 15 earlier versionsHide 15 earlier versions
  1. Trial status: Active, Not Recruiting to Recruiting Primary endpoint revised · Study sites: 15 to 17 · Eligibility criteria shortened, about 28 words · 1 morev16 Show 4 more changesShow less
    • Primary endpoint revised
    • Study sites: 15 to 17
    • Eligibility criteria shortened, about 28 words
    • Secondary endpoints revised (14)

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 114 to 74 Trial status: Recruiting to Active, Not Recruiting · Eligibility criteria expanded, about 26 words · Secondary endpoints: 12 to 14 · 2 morev15 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: 12 to 14
    • Study description shortened, about 84 words
    • Site details revised at 15 of 15 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 14 to 15v14
  4. Site details revised at 1 of 14 sitesv13
  5. Site contacts updated at 1 of 14 sitesv12
  6. Eligibility criteria expanded, about 20 words Site contacts updated at 6 of 14 sitesv11 Show 1 more changeShow less
    • Site contacts updated at 6 of 14 sites

    See this version in full on ClinicalTrials.gov ↗

  7. Site details revised at 1 of 14 sitesv10
  8. Site details revised at 1 of 14 sitesv9
  9. Site details revised at 1 of 14 sitesv8
  10. Site details revised at 2 of 14 sitesv7
  11. Site details revised at 2 of 14 sitesv6
  12. Study sites: 15 to 14v5
  13. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2022 to May 16, 2022 · Site details revised at 15 of 15 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2022 to May 16, 2022
    • Site details revised at 15 of 15 sites
  14. Start date: Feb 2022 to Jun 2022v3
  15. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Trial Details
NCT Number NCT05201469
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Lupus Nephritis
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov